<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003047.pub2" GROUP_ID="LIVER" ID="963700040612194556" MERGED_FROM="" MODIFIED="2014-02-06 11:57:05 +0000" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="04" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.7">
<COVER_SHEET MODIFIED="2014-02-06 11:57:05 +0000" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2012-04-08 20:07:43 +0200" MODIFIED_BY="[Empty name]">Dopamine agents for hepatic encephalopathy</TITLE>
<CONTACT MODIFIED="2014-02-06 11:57:05 +0000" MODIFIED_BY="Dimitrinka Nikolova"><PERSON ID="99313648843967194880110505143017" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anders Ellekær</FIRST_NAME><LAST_NAME>Junker</LAST_NAME><POSITION>MD</POSITION><EMAIL_1>andjunker@dadlnet.dk</EMAIL_1><MOBILE_PHONE>+45 22 77 05 38</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Medicine F</DEPARTMENT><ORGANISATION>Gentofte Hospital</ORGANISATION><ADDRESS_1>Niels Andersens Vej 65</ADDRESS_1><CITY>Hellerup</CITY><ZIP>2900</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 39 77 34 14</PHONE_1><PHONE_2>+45 22 77 05 38</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-02-06 11:57:05 +0000" MODIFIED_BY="Dimitrinka Nikolova"><PERSON ID="99313648843967194880110505143017" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anders Ellekær</FIRST_NAME><LAST_NAME>Junker</LAST_NAME><POSITION>MD</POSITION><EMAIL_1>andjunker@dadlnet.dk</EMAIL_1><MOBILE_PHONE>+45 22 77 05 38</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Medicine F</DEPARTMENT><ORGANISATION>Gentofte Hospital</ORGANISATION><ADDRESS_1>Niels Andersens Vej 65</ADDRESS_1><CITY>Hellerup</CITY><ZIP>2900</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 39 77 34 14</PHONE_1><PHONE_2>+45 22 77 05 38</PHONE_2></ADDRESS></PERSON><PERSON ID="19059" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bodil</FIRST_NAME><LAST_NAME>Als-Nielsen</LAST_NAME><SUFFIX>Ph.D.</SUFFIX><POSITION>Staff Specialist 1., PhD</POSITION><EMAIL_1>bodil.als@dadlnet.dk</EMAIL_1><EMAIL_2>bals0004@rh.regionh.dk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Paediatric Haematology/Oncology (5054)</DEPARTMENT><ORGANISATION>The Child and Youth Clinic</ORGANISATION><ADDRESS_1>Rigshospitalet</ADDRESS_1><ADDRESS_2>University Hospital of Copenhagen</ADDRESS_2><CITY>Copenhagen</CITY><ZIP>2200</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35451898</PHONE_1></ADDRESS></PERSON><PERSON ID="6439" ROLE="AUTHOR"><FIRST_NAME>Christian</FIRST_NAME><LAST_NAME>Gluud</LAST_NAME><SUFFIX>M.D, Dr. Med. Sci.</SUFFIX><POSITION>Head of Department</POSITION><EMAIL_1>cgluud@ctu.dk</EMAIL_1><ADDRESS><DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT><ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION><ADDRESS_1>Blegdamsvej 9</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+ 45 3545 7175</PHONE_1><FAX_1>+ 45 3545 7101</FAX_1></ADDRESS></PERSON><PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR"><FIRST_NAME>Lise Lotte</FIRST_NAME><LAST_NAME>Gluud</LAST_NAME><SUFFIX>M.D., Dr.Med.Sci.</SUFFIX><EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1><ADDRESS><DEPARTMENT>Gastro Unit, Medical Division</DEPARTMENT><ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION><ADDRESS_1>Kettegaards Alle</ADDRESS_1><CITY>Hvidovre</CITY><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>31353212</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-13 17:35:58 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="13" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2014-01-14 11:19:04 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-01-13 17:39:26 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="13" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>No new trials fulfilled the inclusion criteria of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-01-14 11:19:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Searches were updated January 2014, but no new trials were identified for inclusion in the review. New trials are unlikely to be published in the following four years.</P>
<P>The review has been updated based on current methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-13 17:40:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="13" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>AE Junker is the new, lead author of this first review update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-12 13:58:39 +0100" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Copenhagen Trial Unit</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The 1991 Pharmacy Foundation</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Danish Center for Evaluation and Health Technology Assessment (DACEHTA)</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY MODIFIED="2014-01-06 12:42:26 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-12-02 20:07:23 +0100" MODIFIED_BY="[Empty name]">Dopamine agents for hepatic encephalopathy</TITLE>
<SUMMARY_BODY MODIFIED="2014-01-06 12:42:26 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatic encephalopathy is a serious complication of severe liver disease. The disease is often fluctuating with a wide spectrum of symptoms ranging from minor, not readily discernible signs to deep coma. Symptoms often develop in connection to stress related to infection, dehydration, obstipation, or gastrointestinal bleeding. The exact underlying mechanisms behind the disease development are not known. Experimental studies suggest that the mental changes seen in hepatic encephalopathy reflect changes in neurotransmitters in the brain.</P>
<P>Dopamine plays a major role in neurotransmission. Several nervous system diseases including Parkinson's disease are caused by a dysfunction in the dopamine system. Some patients with hepatic encephalopathy have symptoms that are similar to those seen in patients with Parkinson's disease (slow cerebration; stiffness of movements; tremor). For patients with Parkinson's disease, the drugs known as dopamine agents (drugs that mimic the effect of the neurotransmitter dopamine) clearly alleviate symptoms. These drugs have also been assessed for patients with hepatic encephalopathy.</P>
<P>We performed the present systematic review to determine the beneficial and harmful effects of dopamine agents for patients with hepatic encephalopathy. Our analyses included five small trials published in 1982 or earlier. All trials but one had high risks of bias (i.e., risks of systematic errors or risks of overestimation of beneficial effects or risks of underestimation of harmful effects). Only 144 patients were included in the five trials, and accordingly risks of random errors (i.e., play of chance) are present. Our analyses showed no significant differences regarding symptoms of hepatic encephalopathy or mortality in patients treated with dopamine agents compared with patients who received an inactive placebo or no intervention. The number of patients with adverse events seemed comparable in the two intervention groups. Based on the available evidence, we conclude that no evidence can be found to recommend or refute the use of dopamine agents for hepatic encephalopathy. More randomised placebo-controlled clinical trials without risks of systematic errors and risks of random errors seem necessary to obtain firm evidence on dopamine agents for patients with hepatic encephalopathy.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-01-13 17:27:34 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with hepatic encephalopathy may present with extrapyramidal symptoms and changes in basal ganglia. These changes are similar to those seen in patients with Parkinson's disease. Dopamine agents (such as bromocriptine and levodopa, used for patients with Parkinson's disease) have therefore been assessed as a potential treatment for patients with hepatic encephalopathy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-10-17 11:37:02 +0200" MODIFIED_BY="[Empty name]">
<P>To evaluate the beneficial and harmful effects of dopamine agents versus placebo or no intervention for patients with hepatic encephalopathy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-01-13 17:27:34 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were identified through the Cochrane Hepato-Biliary Group Controlled Trials Register (January 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12 of 12, 2013), MEDLINE (1946 to January 2014), EMBASE (1974 to January 2014), and Science Citation Index-Expanded (1900 to January 2014). Manual searches in reference lists, conference proceedings, and online trial registers were also performed.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-01-06 12:41:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trials were included, irrespective of publication status or language. The primary analyses included data from randomised trials using a parallel-group design or the first period of cross-over trials. Paired data from cross-over trials were included in sensitivity analyses.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-01-06 12:41:58 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors extracted data independently. Random-effects meta-analyses were performed as the result of an expected clinical heterogeneity. Fixed-effect meta-analyses, meta-regression analyses, subgroup analyses, and sensitivity analyses were performed to evaluate sources of heterogeneity and bias (systematic errors). Trial sequential analysis was used to control the risk of play of chance (random errors).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-01-10 12:25:39 +0100" MODIFIED_BY="[Empty name]">
<P>Five trials that randomly assigned 144 participants with overt hepatic encephalopathy that were published during 1979 to 1982 were included. Three trials assessed levodopa, and two trials assessed bromocriptine. The mean daily dose was 4 grams for levodopa and 15 grams for bromocriptine. The median duration of treatment was 14 days (range seven to 56 days). None of the trials followed participants after the end of treatment. Only one trial reported adequate bias control; the remaining four trials were considered to have high risk of bias. Random-effects model meta-analyses showed that dopamine agents had no beneficial or detrimental effect on hepatic encephalopathy in the primary analyses (15/80 (19%) versus 14/80 (18%); odds ratio (OR) 2.99, 95% confidence interval (CI) 0.09 to 100.55; two trials) or when paired data from cross-over trials were included (OR 1.04, 95% CI 0.75 to 1.43). Clear evidence of intertrial heterogeneity was identified both in the primary analysis (I<SUP>2</SUP> = 65%) and when paired data from cross-over trials were included (I<SUP>2</SUP> = 40%).</P>
<P>Dopamine agents had no beneficial or harmful effect on mortality (42/144 (29%) versus 38/144 (26%); OR 1.11, 95% CI 0.35 to 3.54; five trials). Trial sequential analyses demonstrated that we lacked information to refute or recommend the interventions for all outcomes. Dopamine agonists did not seem to increase the risk of adverse events.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-01-06 12:42:18 +0100" MODIFIED_BY="[Empty name]">
<P>This review found no evidence to recommend or refute the use of dopamine agents for hepatic encephalopathy. More randomised placebo-controlled clinical trials without risks of systematic errors and risks of random errors seem necessary to permit firm decisions on dopamine agents for patients with hepatic encephalopathy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND MODIFIED="2014-01-06 14:59:53 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-01-06 14:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatic encephalopathy is a complex neuropsychiatric syndrome seen in severe liver failure (<LINK REF="REF-Gitlin-1996" TYPE="REFERENCE">Gitlin 1996</LINK>; <LINK REF="REF-Ferenci-2002" TYPE="REFERENCE">Ferenci 2002</LINK>). Symptoms range from minor neuropsychiatric changes to deep coma (<LINK REF="REF-Conn-1979" TYPE="REFERENCE">Conn 1979</LINK>). Hepatic encephalopathy may be clinically overt or may consist of mild neurocognitive impairments, which have been identified in a substantial percentage of patients with liver disease (<LINK REF="REF-Randolph-2009" TYPE="REFERENCE">Randolph 2009</LINK>). The course of the disease may be episodic, with recurrent symptoms, or chronic, with more stable symptoms (<LINK REF="REF-Bajaj-2011" TYPE="REFERENCE">Bajaj 2011</LINK>). The exact underlying pathophysiology is not known. Experimental studies suggest that symptoms develop as the result of accumulation of toxic agents that have not been metabolised by the liver (<LINK REF="REF-Gitlin-1996" TYPE="REFERENCE">Gitlin 1996</LINK>). Other potential mechanisms include the generation of false neurotransmitters and an abnormal interaction between astrocytes and other cellular elements with cerebral oedema and alterations in glioneural communication (<LINK REF="REF-Haussinger-2000" TYPE="REFERENCE">Haussinger 2000</LINK>; <LINK REF="REF-Cordoba-2001" TYPE="REFERENCE">Cordoba 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-01-06 14:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Many patients with hepatic encephalopathy present with extrapyramidal symptoms and have changes in the basal ganglia, as detected by magnetic resonance imaging and proton spectroscopy (<LINK REF="REF-Spahr-2000" TYPE="REFERENCE">Spahr 2000</LINK>). These symptoms are comparable with those seen in Parkinson's disease and suggest an impairment of dopamine neurotransmission (<LINK REF="REF-Blei-1999" TYPE="REFERENCE">Blei 1999</LINK>; <LINK REF="REF-Jover-2003" TYPE="REFERENCE">Jover 2003</LINK>). Patients with Parkinson's disease are less likely to experience dyskinesia and dystonia when treated with levodopa (<LINK REF="REF-Stowe-2008" TYPE="REFERENCE">Stowe 2008</LINK>). Uncontrolled trials suggest that levodopa or bromocriptine could be beneficial in the treatment of patients with hepatic encephalopathy (<LINK REF="REF-Parkes-1970" TYPE="REFERENCE">Parkes 1970</LINK>; <LINK REF="STD-Jorge-1973" TYPE="STUDY">Jorge 1973</LINK>). The effects of dopamine agents have also been assessed in randomised clinical trials (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>), and previous guidelines suggested that the intervention may be considered in patients with chronic hepatic encephalopathy (<LINK REF="REF-Blei-1999" TYPE="REFERENCE">Blei 1999</LINK>; <LINK REF="REF-Lizardi_x002d_Cervera-2003" TYPE="REFERENCE">Lizardi-Cervera 2003</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-01-06 12:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>We have previously published a systematic review on dopamine agents for hepatic encephalopathy (<LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>). The results of this review were inconclusive. We have been unable to identify any further meta-analyses or systematic reviews on the topic. To determine the strengths and weaknesses of the current evidence, we have updated our previous review (<LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-01-06 12:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the beneficial and harmful effects of dopamine agents versus placebo or no intervention for patients with hepatic encephalopathy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<SELECTION_CRITERIA MODIFIED="2014-01-06 12:43:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_STUDIES MODIFIED="2014-01-06 12:42:52 +0100" MODIFIED_BY="[Empty name]">
<P>This review included all randomised trials, regardless of publication status, language, or blinding. Unpublished trials were included if the methodology and the data were available in written form. We planned to include observational studies reporting harms, but we identified no observational studies reporting relevant data.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-01-06 12:42:57 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with hepatic encephalopathy were included, irrespective of the aetiology of the underlying liver disease. The diagnostic criteria could include psychometric tests, clinical scoring systems (such as the West-Haven criteria), electroencephalography (<LINK REF="REF-Guerit-2009" TYPE="REFERENCE">Guerit 2009</LINK>), or biochemical findings (including ammonia levels). Based on the diagnostic criteria used in the included trials, participants were classified as having overt or minimal hepatic encephalopathy, and the latter was classified further as recurrent or chronic.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-01-06 12:43:03 +0100" MODIFIED_BY="[Empty name]">
<P>The intervention comparisons assessed were dopamine agents (e.g., levodopa, bromocriptine) versus placebo or no intervention. Studies were included irrespective of the dose or duration of therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-01-06 12:43:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-01-06 12:43:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality (all-cause).</LI>
<LI>All cause non-fatal serious adverse events.</LI>
<LI>Morbidity. This outcome measure was assessed on the basis of the number of participants who showed no improvement in manifestations of hepatic encephalopathy as defined by the authors of included trials.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-01-06 12:43:13 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>All-cause non-serious adverse events (number and type) (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</LI>
<LI>Qualitiy of life.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-01-06 12:43:19 +0100" MODIFIED_BY="dimitrinka nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2014-01-06 12:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and Science Citation Index-Expanded (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). Search strategies with time spans of the searches are given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-01-06 12:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>Reference lists in relevant articles and conference proceedings were scanned for additional trials not identified in the electronic searches. We wrote to authors of identified trials and pharmaceutical companies to enquire about additional trials. Ongoing and completed trials were also identified through searches in the World Health Organization Trial Search Portal (<A HREF="http://www.who.int/trialsearch">www.who.int/trialsearch</A>/).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDY_SELECTION MODIFIED="2014-01-06 12:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>All review authors participated in the selection of trials. AEJ listed the potentially eligible trials. Subsequently, trials that fulfilled all inclusion criteria were identified. Excluded trials were listed along with the reasons for exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-01-06 12:43:29 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors (AEJ, BA-N, and LLG) extracted data independently. All disagreements were resolved through discussion before analyses.</P>
<P>We extracted data on the design of the trial (country of origin, parallel or cross-over design, and bias control), participant characteristics (aetiology of underlying liver diseases and type of hepatic encephalopathy, mean age, proportion of men), and the intervention regimen assessed (type, dose, and duration of therapy).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-01-10 12:27:17 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias in the trials independently in accordance with the instructions provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>). Because of the risk of overestimation of intervention effects in randomised trials with high risk of bias (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>, <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>), we assessed the influence of risk of bias on trial results using the following domains.</P>
<P>
<B>Allocation sequence generation</B>
</P>
<UL>
<LI>Low risk of bias: Sequence generation was achieved by using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial.</LI>
<LI>Uncertain risk of bias: The method of sequence generation was not specified.</LI>
<LI>High risk of bias: The sequence generation method was not random.</LI>
</UL>
<P>
<B>Allocation concealment</B>
</P>
<UL>
<LI>Low risk of bias: The participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Uncertain risk of bias: The method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: The allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
<P>
<B>Blinding of participants, personnel, and outcome assessors</B>
</P>
<UL>
<LI>Low risk of bias: Blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding.</LI>
<LI>Uncertain risk of bias: Information was insufficient to permit assessment of whether blinding was likely to induce bias on the results.</LI>
<LI>High risk of bias: No blinding or incomplete blinding was performed, and assessment of outcomes was likely to be influenced by lack of blinding.</LI>
</UL>
<P>
<B>Incomplete outcome data</B>
</P>
<UL>
<LI>Low risk of bias: Missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, had been employed to handle missing data.</LI>
<LI>Uncertain risk of bias: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: The results were likely to be biased as the result of missing data.</LI>
</UL>
<P>
<B>Selective outcome reporting</B>
</P>
<UL>
<LI>Low risk of bias: All outcomes were predefined and reported, or all clinically relevant and reasonably expected outcomes were reported. The trial was registered on the <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> web site or on a similar register, or the protocol was published.</LI>
<LI>Uncertain risk of bias: It was unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported.</LI>
<LI>High risk of bias: One or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded.</LI>
</UL>
<P>
<B>Other bias</B>
</P>
<UL>
<LI>Low risk of bias: The trial appears to be free of other components that could put it at risk of bias. </LI>
<LI>Uncertain risk of bias: The trial may or may not be free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias: Other factors in the trial could put it at risk of bias (e.g., for-profit involvement, authors conducting trials on the same topic).</LI>
</UL>
<P>Trials with unclear or high risk of bias methodology in one or more of the above domains were considered trials with high risk of bias. The remaining were considered trials with low risk of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-01-06 12:43:47 +0100" MODIFIED_BY="[Empty name]">
<P>All outcome measures were dichotomised and were expressed using odds ratios (ORs) with 95% confidence intervals (CIs).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-01-06 12:44:02 +0100" MODIFIED_BY="[Empty name]">
<P>The primary analyses included data from trials using a parallel-group design and from the first treatment period of cross-over trials. Additional analyses were performed that included paired data from the cross-over trials (<LINK REF="REF-Becker-1993" TYPE="REFERENCE">Becker 1993</LINK>; <LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-02-06 07:42:20 +0100" MODIFIED_BY="[Empty name]">
<P>Data on all participants randomly assigned were sought to allow intention-to-treat analyses that included participants irrespective of compliance or follow-up. For participants with missing data, carry-forward of the last observed response was used. We originally planned to analyse the influence of missing data using imputation (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We planned to impute missing values as failures, successes, same as control group, same as experimental group, and same as own group (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We did not perform these analyses because no losses to follow-up were described.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-01-06 12:43:55 +0100" MODIFIED_BY="[Empty name]">
<P>Intertrial heterogeneity was assessed on the basis of I<SUP>2 </SUP>values.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-01-06 12:43:55 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to evaluate the risk of reporting bias by comparing trial protocols and published reports. Furthermore, reporting biases were assessed on the basis of the extent to which clinically relevant outcome measures (hepatic encephalopathy, mortality, and adverse events) were reported.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-01-10 12:02:36 +0100" MODIFIED_BY="[Empty name]">
<P>Analyses were performed in Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and in <LINK REF="REF-STATA-12" TYPE="REFERENCE">STATA 12</LINK> (<LINK REF="REF-STATA-12" TYPE="REFERENCE">STATA 12</LINK>). Primary meta-analyses were performed by using random-effects models because of anticipated variability between trials regarding participants and interventions.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>Originally, we planned to perform several subgroup analyses to assess sources of intertrial heterogeneity (bias control, participant characteristics, and intervention regimens). However, because of the limited number of trials in the meta-analyses of the primary outcomes, we were able to perform these subgroup analyses only for the outcome measure of mortality. Likewise, regression analyses (Egger's test) that were planned to estimate the risk of publication bias and other biases (small-study effects) were performed only for the outcome measure of mortality.</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>We performed trial sequential analysis (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>) to control risks of random errors due to sparse data and repetitive testing of cumulative data (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). To minimise the risk of random error, we calculated the required information size, defined as the required sample size necessary to detect or reject intervention effects after adjusting for diversity (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009;</LINK> <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). The information size was calculated on the basis of a risk ratio (RR) reduction of 20% or the results of included trials with a low risk of bias (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009;</LINK> <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). We presented the results of the analysis in a graph. with individual trials added on the basis of their year of publication. If more than one trial was published in a year, trials were added alphabetically according to the first author's family name. The results of the trials were presented as a cumulative Z-curve. The trial sequential monitoring boundaries were constructed and the diversity-adjusted required information size calculated with a type 1 error of 5% and a type 2 error of 20%. The results were displayed as a graph with the cumulative meta-analysis results entered. The trial sequential analysis shows firm evidence of intervention effects (or no intervention effects) if the cumulative Z-curve crosses the monitoring boundaries; it also shows that additional trials may be needed if the boundaries are not crossed.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-01-06 12:44:11 +0100" MODIFIED_BY="[Empty name]">
<P>The robustness of the results was assessed by repeating the meta-analyses using a fixed-effect model. No additional sensitivity analyses were performed because of the limited number of trials identified.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-01-13 17:32:10 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-01-13 17:32:10 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-01-13 17:32:10 +0100" MODIFIED_BY="[Empty name]">
<P>In total, 294 references were identified through the literature searches (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). After duplicates and clearly irrelevant references (references to papers that did not describe trials of dopaminergic agents for participants with hepatic encephalopathy) were excluded, 17 references were retrieved for further assessment (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Of these, eight references referred to five randomised trials that were eligible for inclusion (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Vij-1979" TYPE="STUDY">Vij 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>; <LINK REF="STD-Koshy-1982" TYPE="STUDY">Koshy 1982</LINK>). Through correspondence with the authors of two trials (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>), additional information was obtained on trial results and methods. For the remaining trials, data were gathered from published reports.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-01-10 12:25:53 +0100" MODIFIED_BY="[Empty name]">
<P>All of the included trials were described in at least one full-paper article published from 1979 to 1982. Three trials used a parallel-group design (<LINK REF="STD-Vij-1979" TYPE="STUDY">Vij 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Koshy-1982" TYPE="STUDY">Koshy 1982</LINK>), and two trials used a cross-over design (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>).</P>
<P>In total, 144 participants with overt hepatic encephalopathy were included. Three trials (66 participants in the treatment group versus 65 participants in the control group) assessed acute episodes of hepatic encephalopathy (<LINK REF="STD-Vij-1979" TYPE="STUDY">Vij 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980;</LINK> <LINK REF="STD-Koshy-1982" TYPE="STUDY">Koshy 1982</LINK>). Two trials (seven participants in the treatment group versus six participants in the control group) assessed chronic hepatic encephalopathy (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). Two trials included participants with acute fulminant liver failure due to viral hepatitis (<LINK REF="STD-Vij-1979" TYPE="STUDY">Vij 1979</LINK>; <LINK REF="STD-Koshy-1982" TYPE="STUDY">Koshy 1982</LINK>). Three trials included participants with cirrhosis (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). The proportion of participants with alcoholic liver disease ranged from 0 to 80%. The proportion of participants with viral hepatitis ranged from 0 to 100%, and mean age ranged from 32 years to 57 years.</P>
<P>Three trials assessed levodopa (<LINK REF="STD-Vij-1979" TYPE="STUDY">Vij 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980;</LINK> <LINK REF="STD-Koshy-1982" TYPE="STUDY">Koshy 1982</LINK>), and two trials assessed bromocriptine (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). The mean daily dose was 4 grams for levodopa and 15 grams for bromocriptine. The median duration of treatment was 14 days (range seven to 56 days). None of the trials followed participants after the end of treatment. None of the included trials assessed health economics.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-10-17 11:48:20 +0200" MODIFIED_BY="[Empty name]">
<P>Nine references to eight trials were excluded because they turned out not to be randomised or referred to cross-over trials that compared dopamine agents versus interventions for hepatic encephalopathy considered potentially active (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-01-06 15:05:42 +0100" MODIFIED_BY="[Empty name]">
<P>All trials had a high risk of bias in the assessment of one or more than one of the bias risk domains.</P>
<ALLOCATION MODIFIED="2014-01-06 15:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation methods (allocation sequence generation and allocation concealment) were classed as adequate in two trials (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>) and unclear in the remaining trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-01-06 15:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>Three trials were blinded using a placebo (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). No blinding was described in the remaining trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-01-06 15:05:29 +0100" MODIFIED_BY="[Empty name]">
<P>Two trials accounted for all participants with missing outcome data (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). In the remaining three trials, no dropouts or withdrawals were described, giving the impression that no losses to follow-up occurred, although this was not specifically stated.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-01-06 15:05:42 +0100" MODIFIED_BY="[Empty name]">
<P>We were able to extract data on hepatic encephalopathy from only three trials (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-10-10 11:21:38 +0200" MODIFIED_BY="[Empty name]">
<P>No sample size calculations were reported. None of the included trials received industry funding.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-01-10 11:59:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>Random-effects meta-analyses found no difference in mortality between participants randomly assigned to dopamine agents versus controls (OR 1.11, 95% CI 0.34 to 3.54; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Little intertrial heterogeneity was noted (I<SUP>2</SUP> = 28%). The result was confirmed in a fixed-effect meta-analysis (OR 1.24, 95% CI 0.59 to 2.59). No evidence of small-study effects was identified in regression analysis (Egger's test P value 0.35). In subgroup analyses, no clear differences were seen between trials on participants with acute episodes compared with chronic hepatic encephalopathy (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) or participants with fulminant liver failure or cirrhosis (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), trials on levodopa or bromocriptine (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), trials with a low or unclear risk of bias (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), or trials using a parallel or cross-over design (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>The trial sequential analysis graph showed that the cumulative Z-curve does not cross the monitoring boundary (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The analysis showed a diversity-adjusted required information size of 673 participants (the number of participants needed to reach firm evidence of an intervention effect of 20% risk ratio reduction). The number of participants included corresponds to only 21% of the diversity-adjusted required information size. Accordingly, we lack evidence to recommend or refute dopamine agents for hepatic encephalopathy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Hepatic encephalopathy</HEADING>
<P>The primary random-effects meta-analyses showed no significant effects of dopamine agents on hepatic encephalopathy compared with placebo or no intervention when data from parallel-group trials were analysed (OR 0.33, 95% CI 0.01 to 11.25; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) or when paired data from the cross-over trial reporting this outcome measure were included (OR 0.68, 95% CI 0.17 to 2.67; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The results were confirmed by fixed-effect meta-analyses including data from parallel-group trials (OR 1.08, 95% CI 0.45 to 2.62), but also when paired data from the two cross-over trials reporting this outcome measure were included (OR 1.04, 95% CI 0.75 to 1.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>We were able to retrieve data on adverse events only from the two cross-over trials (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). In total, seven of 13 participants experienced non-serious adverse events during treatment with dopamine agents. No adverse events were reported during control periods. No clear difference was observed between intervention and control groups (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). No serious adverse events were registered. Adverse events included hypomania (n = 1), hallucinations and headache (n = 1), constipation (n = 3), and nausea and vomiting (n = 2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>None of the included trials reported data on quality of life.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with cirrhosis may present with extrapyramidal symptoms similar to those seen in Parkinson's disease (<LINK REF="REF-Jover-2003" TYPE="REFERENCE">Jover 2003</LINK>). Further similarities between participants with hepatic encephalopathy and participants with Parkinson's disease include alterations in the basal ganglia (<LINK REF="REF-Spahr-2000" TYPE="REFERENCE">Spahr 2000</LINK>). In theory, dopamine agents that are effective in Parkinson's disease could alleviate manifestations of hepatic encephalopathy. However, the present systematic review found no evidence to recommend or refute the use of dopamine agents for patients with hepatic encephalopathy. The available evidence includes only a limited number of small trials published before 1983. No clear effects were identified for any of the outcome measures assessed. Additional analyses found no specific subgroups that indicated potential effects when the results of included trials were separated on the basis of the type of hepatic encephalopathy at inclusion, the type of underlying liver disease, or the intervention assessed. The dose and duration of the interventions assessed were similar across trials. Data from participants with Parkinson's disease (<LINK REF="REF-Miyasaki-2002" TYPE="REFERENCE">Miyasaki 2002</LINK>) show that the dose of both levodopa and bromocriptine and the duration of the intervention regimens assessed in included trials should be sufficiently high to detect a clinical response. The combined evidence is not promising. However, the statistical power is low, and evidence is insufficient to support or refute beneficial or harmful effects of the interventions assessed.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-01-06 12:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>To ensure completeness of the evidence, we performed extensive literature searches. Our regression analyses showed no clear evidence of publication bias or other small-study effects. Still, the regression analysis was not sensitive because of the limited number of trials.</P>
<P>The main problem with the included trials is the fact that a number of potentially effective interventions for patients with decompensated liver disease have been identified after the trials were completed. These interventions include treatments for hepatic encephalopathy (<LINK REF="REF-Bass-2010" TYPE="REFERENCE">Bass 2010</LINK>), bleeding oesophageal varices (<LINK REF="REF-Abraldes-2007" TYPE="REFERENCE">Abraldes 2007</LINK>), and spontaneous bacterial peritonitis (<LINK REF="REF-Wiest-2012" TYPE="REFERENCE">Wiest 2012</LINK>). Likewise, the diagnostic assessment and nomenclature for hepatic encephalopathy have been updated (<LINK REF="REF-Bajaj-2011" TYPE="REFERENCE">Bajaj 2011</LINK>). Accordingly, extrapolation of results from the present review to current clinical practice is of limited value.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>Adequate internal validity depends on the control of bias and random errors. Because three trials had unclear randomisation (<LINK REF="STD-Michel-1980" TYPE="STUDY">Michel 1980</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>; <LINK REF="STD-Koshy-1982" TYPE="STUDY">Koshy 1982</LINK>) and consequently an unclear control of selection bias, the internal validity of their results and of the results of our meta-analyses can be questioned. The use of a cross-over design as applied in two of the included trials (<LINK REF="STD-Uribe-1979" TYPE="STUDY">Uribe 1979</LINK>; <LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>) is also debatable. Even chronic hepatic encephalopathy may have a fluctuating course (<LINK REF="REF-Basile-1991" TYPE="REFERENCE">Basile 1991</LINK>); therefore, manifestations of hepatic encephalopathy may change during the course of the trial, irrespective of the interventions assessed. The underlying condition and the ability to respond to treatment may not remain stable from the first to the second treatment period. We therefore used only data from the first study period of the cross-over trials in our primary analyses. Unfortunately, these data were available for only one trial (<LINK REF="STD-Morgan-1980" TYPE="STUDY">Morgan 1980</LINK>). The sensitivity analysis on paired data did not change our overall result.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-02-06 07:43:13 +0100" MODIFIED_BY="[Empty name]">
<P>Identification and selection of trials are essential to the assessment of bias in the review process. To limit bias in the selection process, we included trials irrespective of language or publication status. We also chose to include trials regardless of the dose or duration of the interventions assessed. This led to a relatively heterogeneous group of trials. We did, however, choose to exclude trials with an active comparison group. This choice was made on the basis of lack of evidence supporting several of the interventions assessed for patients with hepatic encephalopathy. The strategy resulted in the exclusion of two small, low-quality, cross-over trials on chronic hepatic encephalopathy (<LINK REF="STD-Messner-1982" TYPE="STUDY">Messner 1982</LINK>; <LINK REF="STD-Uribe-1983" TYPE="STUDY">Uribe 1983</LINK>). The control groups in these trials received lactulose or neomycin, which could affect the course of hepatic encephalopathy. The total number of participants randomly assigned in these two trials was only 15, and this limits the value of these results.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-01-09 19:16:24 +0100" MODIFIED_BY="[Empty name]">
<P>At present, dopamine agents are not recommended for patients with hepatic encephalopathy. Previous guidelines state that bromocriptine may be considered for patients with chronic hepatic encephalopathy that is unresponsive to other interventions (<LINK REF="REF-Blei-1999" TYPE="REFERENCE">Blei 1999</LINK>). In agreement with more recent recommendations (<LINK REF="REF-Phongsamran-2010" TYPE="REFERENCE">Phongsamran 2010</LINK>), the present review contradicts these recommendations, suggesting that no evidence is available to support the use of dopamine agents for chronic hepatic encephalopathy.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-01-09 19:14:58 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-17 11:52:02 +0200" MODIFIED_BY="[Empty name]">
<P>This review does not provide evidence to recommend or refute the use of dopamine agents for patients with hepatic encephalopathy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-01-09 19:14:58 +0100" MODIFIED_BY="[Empty name]">
<P>However, we cannot exclude the possibility that dopamine agents may have beneficial effects that were overlooked because of the limited statistical power of the included trials. On the other hand, other interventions for hepatic encephalopathy (such as non-absorbable disaccharides, branched chain amino acids, and antibiotics) appear potentially more promising than dopamine agents (<LINK REF="REF-Als_x002d_Nielsen-2004a" TYPE="REFERENCE">Als-Nielsen 2004a</LINK>; <LINK REF="REF-Bass-2010" TYPE="REFERENCE">Bass 2010</LINK>; <LINK REF="REF-Les-2011" TYPE="REFERENCE">Les 2011</LINK>). The value of additional trials on dopamine agents is questionable. Should anyone wish to conduct further trials, we recommend that the dopamine agent used should be tested against placebo in parallel-group superiority trials conducted according to the SPIRIT guidelines (<LINK REF="REF-SPIRIT-2013" TYPE="REFERENCE">SPIRIT 2013</LINK>; <LINK REF="REF-SPIRIT-2013a" TYPE="REFERENCE">SPIRIT 2013a</LINK>) and reported according to the CONSORT guidelines (<A HREF="http://www.consort-statement.org">www.consort-statement.org</A>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-01-06 12:44:50 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Marsha Morgan and Misael Uribe for providing additional information on their trials, and Sarah Klingenberg for performing the electronic literature searches.</P>
<P>Peer reviewers: FG Romeiro, Brazil; Diego Sánchez-Munoz, Spain.<BR/>Contact editor: Goran Bjelakovic, Serbia.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-01-09 19:16:22 +0100" MODIFIED_BY="[Empty name]">
<P>Anders Ellekær Junker (AEJ) and Lise Lotte Gluud (LLG) drafted the revised version of this updated review with methodology updates based on the most recent recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). AEJ, Bodil Als-Nielsen (BA-N), and LLG participated in the literature searches, identified trials eligible for inclusion, extracted data, and performed the statistical analyses. All authors revised the review and have approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-01-06 12:45:08 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>We have changed the term 'dopaminergic agents' to the MeSH term 'dopamine agents' throughout the review.</LI>
<LI>Based on reviewer comments, we have omitted the outcome 'Number of participants with hepatic encephalopathy recovery' because the definition of this outcome is highly variable. The outcome of (lack of) improvement in hepatic encephalopathy includes participants with complete as well as partial recovery from hepatic encephalopathy.</LI>
<LI>In our original protocol, we planned to include health economics as an outcome. This outcome was omitted from our previous and present review on the basis of reviewer comments and evidence concerning the best methods for assessing this outcome. We have gathered data on whether health economics were assessed and have included these data in our table of included trials.</LI>
<LI>Based on the most recent recommendations regarding the assessment of bias control, we have included bias tables and have assessed the bias control components of allocation (selection bias), blinding (performance bias and detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other potential sources of bias (sample size assessments).</LI>
<LI>We have included additional analyses on small-study effects (Egger's test).  </LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-01-10 12:18:43 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-01-10 12:03:50 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDIES MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Koshy-1982" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Koshy 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koshy A, Pratap B, Datta DV</AU>
<TI>Prospective randomised controlled trial of L-dopa and hydrocortisone in fulminant hepatitis</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>9</NO>
<PG>613-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7184928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michel-1980" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Michel 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="OTHER">
<AU>Michel H, Cauvet G, Granier PM, Bali JP, Cuilleret A, Cuilleret G</AU>
<TI>Treatment of cirrhotic hepatic encephalopathy by L-dopa. A double-blind study of 58 patients [abstract]</TI>
<SO>Digestion</SO>
<YR>1977</YR>
<VL>15</VL>
<PG>232-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Michel H, Solere M, Granier P, Cauvet G, Bali JP, Pons F, et al</AU>
<TI>Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1980</YR>
<VL>79</VL>
<NO>2</NO>
<PG>207-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6995221"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-1980" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Morgan 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="OTHER">
<AU>Morgan MY, Jakobovits AW, James IM, Lennox R, Sherlock S</AU>
<TI>Bromocriptine in the treatment of chronic portal systemic encephalopathy [abstract]</TI>
<SO>Gut</SO>
<YR>1978</YR>
<VL>19</VL>
<NO>Suppl 2</NO>
<PG>A453</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morgan MY, Jakobovits AW, James IM, Sherlock S</AU>
<TI>Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy</TI>
<SO>Gastroenterology</SO>
<YR>1980</YR>
<VL>78</VL>
<NO>4</NO>
<PG>663-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7353752"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Morgan MY</AU>
<TI>Bromocriptine in the treatment of chronic hepatic encephalopathy</TI>
<SO>Hepatic Encephalopathy in Chronic Liver Failure</SO>
<YR>1984</YR>
<PG>255-65</PG>
<ED>Capocaccia L, Fischer JE, Rossi-Fanelli F</ED>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uribe-1979" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Uribe 1979" YEAR="1979">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uribe M, Farca A, Marquez MA, Garcia Ramos G, Guevara L</AU>
<TI>Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial</TI>
<SO>Gastroenterology</SO>
<YR>1979</YR>
<VL>76</VL>
<NO>6</NO>
<PG>1347-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="374177"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vij-1979" MODIFIED="2012-04-08 20:04:47 +0200" MODIFIED_BY="[Empty name]" NAME="Vij 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vij JC, Tandon BN</AU>
<TI>Controlled trial of levodopa in fulminant hepatitis</TI>
<SO>Indian Journal of Medical Research</SO>
<YR>1979</YR>
<VL>69</VL>
<PG>624-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 378825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Catalano-1982" MODIFIED="2014-01-06 14:20:54 +0100" MODIFIED_BY="[Empty name]" NAME="Catalano 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-01-06 14:20:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catalano D, Trovato G, Vancheri F, Mazzone O</AU>
<TI>Bromocriptine in the treatment of chronic hepatic encephalopathy refractory to conventional treatment: crossover trial with levodopa-benserazide</TI>
<SO>Current Therapeutic Research</SO>
<YR>1982</YR>
<VL>32</VL>
<PG>544-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1982249532"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Datta-1976" MODIFIED="2014-01-06 15:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Datta 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-01-06 15:07:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Datta DV, Maheshwari YK, Aggarwal ML</AU>
<TI>Levodopa in fulminant hepatic failure: preliminary report</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>1976</YR>
<VL>272</VL>
<PG>95-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 961722"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorge-1973" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Jorge 1973" YEAR="1973">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jorge AD, Sanchez D</AU>
<TI>Effect of L-dopa on hepatic coma</TI>
<TO>Die Wirkung des L-Dopa im Coma hepaticum</TO>
<SO>Schweizerische Rundschau für Medizin Praxis</SO>
<YR>1973</YR>
<VL>62</VL>
<NO>27</NO>
<PG>868-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4578027"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lunzer-1974" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Lunzer 1974" YEAR="1974">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lunzer M, James IM, Weinman J, Sherlock S</AU>
<TI>Treatment of chronic hepatic encephalopathy with levodopa</TI>
<SO>Gut</SO>
<YR>1974</YR>
<VL>15</VL>
<NO>7</NO>
<PG>555-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4430473"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Messner-1982" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Messner 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Messner M, Le Gall J-Y, Toulouse P, Javaudin L, Delamaire D, Brissot P, et al</AU>
<TI>Plasma ratio of branched chain/aromatic amino acids during treatment of chronic hepatic encephalopathy using lactulose/bromocriptine in a double blind procedure [EASL abstract]</TI>
<SO>Liver</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>3 Pt 2</NO>
<PG>312</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 1983020208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pascual-1979" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Pascual 1979" YEAR="1979">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pascual Izuel JM, Peces Serrano R, Hernandez Guio C</AU>
<TI>Role of bromocriptine in the treatment of chronic hepatic encephalopathy</TI>
<TO>Interes de la bromocriptina en el tratamiento de la encefalopatia hepatica cronica</TO>
<SO>Revista Clinica Espanola</SO>
<YR>1979</YR>
<VL>155</VL>
<NO>3</NO>
<PG>219-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="397554"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trovato-1982" NAME="Trovato 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trovato GM, Catalano D, Vancheri FS, Mazzone O</AU>
<TI>Successful use of amantadine and levodopa-benserazide in chronic portal systemic encephalopathy. A crossover trial with conventional therapy</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1982</YR>
<VL>31</VL>
<PG>625-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 1982138453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ubiria-1980" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Ubiria 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ubiria J, Morales M, Vila A, Farre A, Balanzo J</AU>
<TI>Treatment of chronic portosystemic encephalopathy with bromocriptine</TI>
<TO>Tratamiento de la encefalopatía crónica portosistémica (E.C.P.S.) con bromocriptina</TO>
<SO>Revista Espanola de Las Enfermedades del Aparato Digestivo</SO>
<YR>1980</YR>
<VL>58</VL>
<NO>1</NO>
<PG>21-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7403629"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uribe-1983" MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Uribe 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-01-10 12:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Uribe M, Garcia Ramos G, Ramos M, Valverde C, Marquez MA, Farca A, et al</AU>
<TI>Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1983</YR>
<VL>78</VL>
<NO>8</NO>
<PG>517-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6881119"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 13:25:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uribe M, Marquez MA, Guevara L, Garcia Ramos G</AU>
<TI>Bromocriptine for severe chronic portal systemic encephalopathy [abstract]</TI>
<SO>Gastroenterology</SO>
<YR>1982</YR>
<VL>82</VL>
<PG>1201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-01-10 12:03:50 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2014-01-09 19:15:30 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Abraldes-2007" MODIFIED="2014-01-06 14:21:38 +0100" MODIFIED_BY="[Empty name]" NAME="Abraldes 2007" TYPE="JOURNAL_ARTICLE">
<AU>Abraldes JG, Bosch J</AU>
<TI>The treatment of acute variceal bleeding</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>Suppl 3</NO>
<PG>S312-S317</PG>
<IDENTIFIERS MODIFIED="2012-04-08 18:44:20 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17975482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Als_x002d_Nielsen-2004a" MODIFIED="2013-05-23 13:44:01 +0200" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2004a" TYPE="COCHRANE_REVIEW">
<AU>Als-Nielsen B, Gluud LL, Gluud C</AU>
<TI>Nonabsorbable disaccharides for hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-05-23 13:43:31 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 13:43:29 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003044.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bajaj-2011" MODIFIED="2014-01-06 14:21:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bajaj 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al</AU>
<TI>Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>7</NO>
<PG>739-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21306407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Basile-1991" MODIFIED="2013-05-23 13:57:50 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Basile 1991" TYPE="JOURNAL_ARTICLE">
<AU>Basile AS, Jones EA, Skolnick P</AU>
<TI>The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands</TI>
<SO>Pharmacological Reviews</SO>
<YR>1991</YR>
<VL>43</VL>
<NO>1</NO>
<PG>27-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91239624"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bass-2010" MODIFIED="2014-01-06 15:08:59 +0100" MODIFIED_BY="[Empty name]" NAME="Bass 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al</AU>
<TI>Rifaximin treatment in hepatic encephalopathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<NO>12</NO>
<PG>1071-81</PG>
<IDENTIFIERS MODIFIED="2012-04-08 18:25:40 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20335583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Becker-1993" MODIFIED="2013-05-23 13:59:08 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Becker 1993" TYPE="JOURNAL_ARTICLE">
<AU>Becker MP, Balagtas CC</AU>
<TI>Marginal modelling of binary cross-over data</TI>
<SO>Biometrics</SO>
<YR>1993</YR>
<VL>49</VL>
<PG>997-1009</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 8117910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blei-1999" MODIFIED="2014-01-06 14:22:10 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Blei 1999" TYPE="BOOK_SECTION">
<AU>Blei A</AU>
<TI>Hepatic encephalopathy</TI>
<SO>Clinical Hepatology</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>765-83</PG>
<EN>2nd</EN>
<ED>Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodés J</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2013-05-23 12:16:41 +0200" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2014-01-06 14:22:30 +0100" MODIFIED_BY="[Empty name]" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conn-1979" MODIFIED="2014-01-06 14:22:52 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Conn 1979" TYPE="BOOK">
<AU>Conn H, Lieberthal M</AU>
<SO>The Hepatic Coma Syndromes and Lactulose</SO>
<YR>1979</YR>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cordoba-2001" MODIFIED="2008-10-17 15:57:47 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Cordoba 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, et al</AU>
<TI>The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>598-604</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PM 11690705"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CTU-2011" MODIFIED="2014-01-06 15:09:34 +0100" MODIFIED_BY="[Empty name]" NAME="CTU 2011" TYPE="OTHER">
<AU>Copenhagen Trial Unit</AU>
<TI>TSA - Trial Sequential Analysis</TI>
<SO>ctu.dk/tsa/</SO>
<YR>2011 (accessed 4 September 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2008-10-17 15:57:47 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<PG>140-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferenci-2002" MODIFIED="2014-01-06 14:23:35 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Ferenci 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT</AU>
<TI>Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>35</VL>
<PG>716-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PM 11870389"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gitlin-1996" MODIFIED="2014-01-06 14:23:49 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gitlin 1996" TYPE="BOOK_SECTION">
<AU>Gitlin N</AU>
<TI>Hepatic encephalopathy</TI>
<SO>Hepatology. A Textbook of Liver Disease</SO>
<YR>1996</YR>
<VL>1</VL>
<PG>605-17</PG>
<EN>3rd</EN>
<ED>Zakim D, Boyer T</ED>
<PB>WB Saunders Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2013" MODIFIED="2014-01-09 19:15:30 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2013" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>Art. No.: LIVER</SO>
<YR>2013</YR>
<NO>12</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guerit-2009" MODIFIED="2014-01-06 14:24:09 +0100" MODIFIED_BY="[Empty name]" NAME="Guerit 2009" TYPE="JOURNAL_ARTICLE">
<AU>Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, et al</AU>
<TI>Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>6</NO>
<PG>789-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19638107"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haussinger-2000" MODIFIED="2014-01-06 14:25:02 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Haussinger 2000" TYPE="JOURNAL_ARTICLE">
<AU>Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S</AU>
<TI>Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>1035-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 10898326"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2013-11-29 18:19:10 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, White IR, Wood AM</AU>
<TI>Imputation methods for missing outcome data in meta-analysis of clinical trials</TI>
<SO>Clinical Trials</SO>
<YR>2008</YR>
<VL>5</VL>
<PG>225-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-05-23 14:00:02 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Whitehead A, Simmonds M</AU>
<TI>Sequential methods for random-effects meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>9</NO>
<PG>903-21</PG>
<IDENTIFIERS MODIFIED="2012-04-07 23:38:37 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21472757"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2014-01-06 15:11:42 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2014-01-06 14:25:14 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR and ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jover-2003" MODIFIED="2014-01-06 14:25:26 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Jover 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jover R, Company L, Gutierrez A, Zapater P, Perez-Serra J, Girona E, et al</AU>
<TI>Minimal hepatic encephalopathy and extrapyramidal signs in patients with cirrhosis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>1599-604</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12873585"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2013-05-23 12:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Les-2011" MODIFIED="2014-01-06 15:12:06 +0100" MODIFIED_BY="[Empty name]" NAME="Les 2011" TYPE="JOURNAL_ARTICLE">
<AU>Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, et al</AU>
<TI>Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>6</NO>
<PG>1081-8</PG>
<IDENTIFIERS MODIFIED="2012-04-08 18:27:14 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21326220"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lizardi_x002d_Cervera-2003" MODIFIED="2008-10-17 15:57:47 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Lizardi-Cervera 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lizardi-Cervera J, Almeda P, Guevara L, Uribe M</AU>
<TI>Hepatic encephalopathy: a review</TI>
<SO>Annals of Hepatology</SO>
<YR>2003</YR>
<VL>2</VL>
<PG>122-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 15115963"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2013-05-23 12:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miyasaki-2002" MODIFIED="2014-01-06 15:12:22 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Miyasaki 2002" TYPE="JOURNAL_ARTICLE">
<AU>Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE</AU>
<TI>Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology</TI>
<SO>American Academy of Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<PG>11-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="PMID: 12391377"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2013-05-23 12:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkes-1970" MODIFIED="2008-10-17 15:57:47 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Parkes 1970" TYPE="JOURNAL_ARTICLE">
<AU>Parkes JD, Sharpstone P, Williams R</AU>
<TI>Levodopa in hepatic coma</TI>
<SO>Lancet</SO>
<YR>1970</YR>
<VL>2</VL>
<NO>7687</NO>
<PG>1341-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4098911"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Phongsamran-2010" MODIFIED="2012-04-08 19:21:57 +0200" MODIFIED_BY="[Empty name]" NAME="Phongsamran 2010" TYPE="JOURNAL_ARTICLE">
<AU>Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A</AU>
<TI>Pharmacotherapy for hepatic encephalopathy</TI>
<SO>Drugs</SO>
<YR>2010</YR>
<VL>70</VL>
<NO>9</NO>
<PG>1131-48</PG>
<IDENTIFIERS MODIFIED="2012-04-08 19:21:55 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20518580"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Randolph-2009" MODIFIED="2013-05-23 14:02:16 +0200" MODIFIED_BY="[Empty name]" NAME="Randolph 2009" TYPE="JOURNAL_ARTICLE">
<AU>Randolph C, Hilsabeck R, Kato A, Kharbanda P, Li YY, Mapelli D, et al</AU>
<TI>Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>5</NO>
<PG>629-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="19302444"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-05-23 14:02:34 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2013-05-23 12:20:07 +0200" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012" MODIFIED="2014-01-06 15:12:50 +0100" MODIFIED_BY="Christian Gluud" NAME="Savovic 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012a" MODIFIED="2013-05-23 12:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Savovic 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2013-05-23 12:24:42 +0200" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spahr-2000" MODIFIED="2008-10-17 15:57:47 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Spahr 2000" TYPE="JOURNAL_ARTICLE">
<AU>Spahr L, Vingerhoets F, Lazeyras F, Delavelle J, DuPasquier R, Giostra E, et al</AU>
<TI>Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>119</VL>
<PG>774-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10982772"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SPIRIT-2013" MODIFIED="2014-01-06 14:18:37 +0100" MODIFIED_BY="[Empty name]" NAME="SPIRIT 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krle&#382;a-Jeri&#263; K, et al</AU>
<TI>SPIRIT 2013 Statement: defining standard protocol items for clinical trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2013</YR>
<VL>158</VL>
<PG>200-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SPIRIT-2013a" MODIFIED="2014-01-06 15:13:34 +0100" MODIFIED_BY="[Empty name]" NAME="SPIRIT 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al</AU>
<TI>SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2013</YR>
<VL>346</VL>
<PG>e7586</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-STATA-12" MODIFIED="2013-03-21 15:35:05 +0100" MODIFIED_BY="[Empty name]" NAME="STATA 12" TYPE="COMPUTER_PROGRAM">
<TI>STATA 12</TI>
<YR>2012</YR>
<PB>STATACorp LP, Texas USA</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stowe-2008" MODIFIED="2014-01-06 15:15:13 +0100" MODIFIED_BY="[Empty name]" NAME="Stowe 2008" TYPE="COCHRANE_REVIEW">
<AU>Stowe R, Ives N, Clarke CE, van Hilten, Ferreira J, Hawker RJ, et al</AU>
<TI>Dopamine agonist therapy in early Parkinson's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-01-06 15:15:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-06 15:15:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006564.pub2"/>
<IDENTIFIER TYPE="PUBMED" VALUE="18425954"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2013-05-23 12:16:53 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2013-05-23 12:16:53 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2014-01-06 15:15:29 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for Trial Sequential Analysis (TSA)</TI>
<SO>http://ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 23 April 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2014-01-06 14:25:54 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2012-04-07 23:40:43 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18083463"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2014-01-06 14:26:13 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2013-03-21 14:37:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiest-2012" MODIFIED="2012-04-08 18:46:56 +0200" MODIFIED_BY="[Empty name]" NAME="Wiest 2012" TYPE="JOURNAL_ARTICLE">
<AU>Wiest R, Krag A, Gerbes A</AU>
<TI>Spontaneous bacterial peritonitis: recent guidelines and beyond</TI>
<SO>Gut</SO>
<YR>2012</YR>
<VL>61</VL>
<NO>2</NO>
<PG>297-310</PG>
<IDENTIFIERS MODIFIED="2012-04-08 18:46:54 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22147550"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2013-05-23 14:05:49 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2012-04-08 19:26:59 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18316340"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-01-10 12:03:50 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Als_x002d_Nielsen-2004" MODIFIED="2014-01-10 12:03:50 +0100" MODIFIED_BY="[Empty name]" NAME="Als-Nielsen 2004" TYPE="COCHRANE_REVIEW">
<AU>Als-Nielsen B, Gluud LL, Gluud C</AU>
<TI>Dopaminergic agonists for hepatic encephalopathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-05-23 14:08:36 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:08:36 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003047.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-04-07 22:35:24 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-01-06 12:48:26 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-01-06 12:48:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-01-06 12:45:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koshy-1982">
<CHAR_METHODS MODIFIED="2014-01-06 12:45:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Parallel-group trial.</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-18 15:40:44 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Type of hepatic encephalopathy: acute episodes associated with fulminant liver failure.</LI>
</UL>
<UL>
<LI>Type of underlying liver disease: fulminant liver failure due to viral hepatitis (100%).</LI>
</UL>
<UL>
<LI>Mean age: not reported.</LI>
</UL>
<UL>
<LI>Proportion of men: not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 12:45:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Dopamine agent: levodopa 4 grams/d.</LI>
</UL>
<UL>
<LI>Control: no intervention.</LI>
</UL>
<UL>
<LI>Treatment duration: not reported.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-08 15:51:44 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-08 15:51:47 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Health economics: not assessed.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 12:45:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Michel-1980">
<CHAR_METHODS MODIFIED="2014-01-06 12:45:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Parallel-group trial.</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 12:45:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Type of hepatic encephalopathy: acute episodes of hepatic encephalopathy.</LI>
</UL>
<UL>
<LI>Type of liver disease: cirrhosis based on alcohol (80%), viral hepatitis (15%), or cryptogenic (5%).</LI>
</UL>
<UL>
<LI>Mean age: 57 years.</LI>
</UL>
<UL>
<LI>Proportion of men: 80%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 12:45:37 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Dopamine agent: levodopa (2 grams on the first day, then 4 grams/d) alone or with dopa-decarboxylase inhibitor (0.2 gram on the first day, then 0.4 grams/d).</LI>
</UL>
<UL>
<LI>Control: placebo.</LI>
</UL>
<UL>
<LI>Treatment duration: seven days.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-18 15:40:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy and mortality.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-05 21:15:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Health economics: not assessed.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 12:45:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morgan-1980">
<CHAR_METHODS MODIFIED="2013-03-18 15:40:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cross-over trial.</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-18 15:40:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Type of hepatic encephalopathy: chronic hepatic encephalopathy.</LI>
</UL>
<UL>
<LI>Type of liver disease: cirrhosis due to alcohol (60%) or cryptogenic (40%).</LI>
</UL>
<UL>
<LI>Mean age: 51 years.</LI>
</UL>
<UL>
<LI>Proportion of men: 100%.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 12:45:46 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Dopamine agent: bromocriptine 15 mg/d.</LI>
</UL>
<UL>
<LI>Control: placebo.</LI>
</UL>
<UL>
<LI>Treatment duration: eight weeks.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-18 15:40:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy, mortality, and adverse events.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-08 20:26:17 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Health economics: not assessed.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 12:48:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uribe-1979">
<CHAR_METHODS MODIFIED="2013-03-18 15:40:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cross-over trial.</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-29 18:26:40 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Type of hepatic encephalopathy: chronic hepatic encephalopathy.</LI>
</UL>
<UL>
<LI>Type of liver disease: cirrhosis due to alcohol (63%) or viral hepatitis (37%).</LI>
</UL>
<UL>
<LI>Mean age: not reported (range 45 to 78 years).</LI>
</UL>
<UL>
<LI>Proportion of men: 63%.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 12:45:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Dopamine agent: bromocriptine 15 mg/d.</LI>
</UL>
<UL>
<LI>Control: placebo.</LI>
</UL>
<UL>
<LI>Treatment duration: two weeks.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 12:48:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hepatic encephalopathy, mortality, and adverse events.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-08 20:32:04 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Health economics: not assessed.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 12:46:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vij-1979">
<CHAR_METHODS MODIFIED="2014-01-06 12:46:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Parallel-group trial.</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-18 15:40:59 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Type of hepatic encephalopathy: acute episode of hepatic encephalopathy.</LI>
</UL>
<UL>
<LI>Type of liver disease: fulminant liver failure due to viral hepatitis (100%).</LI>
</UL>
<UL>
<LI>Mean age: 32 years.</LI>
</UL>
<UL>
<LI>Proportion of men: not reported.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 12:46:20 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Dopamine agent: levodopa 3 to 4 grams/d.</LI>
</UL>
<UL>
<LI>Control: no intervention.</LI>
</UL>
<UL>
<LI>Treatment duration: not reported.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-08 20:36:57 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-08 20:37:00 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Health economics: not assessed.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-01-06 12:46:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-04-08 17:06:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Catalano-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-08 17:06:57 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-19 10:47:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Datta-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-19 10:47:19 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-08 17:07:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jorge-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-08 17:07:05 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-08 17:07:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lunzer-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-08 17:07:19 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-06 12:46:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Messner-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-06 12:46:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over trial including 11 participants with chronic hepatic encephalopathy comparing bromocriptine with lactulose. Excluded because the control group received an active intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-08 17:08:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pascual-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-08 17:08:23 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-08 17:08:36 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trovato-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-08 17:08:36 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-04-08 17:08:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ubiria-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-04-08 17:08:45 +0200" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-06 12:46:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uribe-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-06 12:46:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised cross-over trial including four participants with chronic hepatic encephalopathy comparing bromocriptine versus neomycin. Excluded because the control group received an active intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-01-06 12:48:15 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-04-08 20:39:09 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 15:48:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koshy-1982">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:39:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1980">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:27:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1980">
<DESCRIPTION>
<P>Computer-generated random number sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:34:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1979">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:37:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vij-1979">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-04-08 20:39:16 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 15:48:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koshy-1982">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:39:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1980">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:27:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1980">
<DESCRIPTION>
<P>Central independent unit.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:33:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1979">
<DESCRIPTION>
<P>Central administration of blinded drug containers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:37:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vij-1979">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-01-06 12:46:15 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-08 15:47:50 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koshy-1982">
<DESCRIPTION>
<P>No blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 12:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michel-1980">
<DESCRIPTION>
<P>Double-blind placebo-controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-08 20:27:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1980">
<DESCRIPTION>
<P>Administration of identical coded drug container.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 12:46:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1979">
<DESCRIPTION>
<P>Double-blind placebo-controlled with additional blinded data analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-04-08 20:38:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vij-1979">
<DESCRIPTION>
<P>Open trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-01-06 12:46:15 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-18 15:40:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koshy-1982">
<DESCRIPTION>
<P>Losses to follow-up not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 12:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1980">
<DESCRIPTION>
<P>No losses to follow-up described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 12:46:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1980">
<DESCRIPTION>
<P>All participants accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 12:46:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1979">
<DESCRIPTION>
<P>All participants accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-18 15:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vij-1979">
<DESCRIPTION>
<P>Losses to follow-up not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-01-06 12:48:15 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 12:48:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koshy-1982">
<DESCRIPTION>
<P>Hepatic encephalopathy not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 16:04:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Michel-1980">
<DESCRIPTION>
<P>Clinically relevant outcome measures defined and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:28:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-1980">
<DESCRIPTION>
<P>Clinically relevant outcome measures defined and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:38:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uribe-1979">
<DESCRIPTION>
<P>Clinically relevant outcome measures defined and reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-18 15:41:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vij-1979">
<DESCRIPTION>
<P>Hepatic encephalopathy not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2012-04-08 20:37:44 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Sample size calculations</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 15:47:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Koshy-1982">
<DESCRIPTION>
<P>No.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 16:05:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Michel-1980">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:28:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morgan-1980">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:34:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uribe-1979">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-08 20:37:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vij-1979">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-01-09 18:56:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-01-09 18:56:27 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-12-02 20:11:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">Dopamine agonists for hepatic encephalopathy</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD COLSPAN="7">
<P>
<B>Dopamine agonists versus placebo or no intervention for hepatic encephalopathy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with hepatic encephalopathy.<BR/>
<B>Settings: </B>hospitalised patients.<BR/>
<B>Intervention:</B> dopamine agonists versus placebo or no intervention.<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control (placebo or no intervention)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Dopamine agonists</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
<BR/>Follow-up: mean one month</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.11 </B>
<BR/>(0.35 to 3.54)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>144<BR/>(five studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>535 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>561 per 1000</B>
<BR/>(287 to 803)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>420 per 1000</B>
<BR/>(186 to 698)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Hepatic encephalopathy</B>
<BR/>Follow-up: mean one month</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 2.99 </B>
<BR/>(0.09 to 100.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>80<BR/>(two studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>350 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>617 per 1000</B>
<BR/>(46 to 982)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>184 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>403 per 1000</B>
<BR/>(20 to 958)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The randomisation methods were classed as adequate in two trials, and three trials were double-blind.<BR/>
<SUP>2</SUP>The sample size was small, and the statistical power of included trials was weak.<BR/>
<SUP>3</SUP>Because of the small number of trials, tests for publication bias were of limited value.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-10-17 15:57:46 +0200" MODIFIED_BY="dimitrinka nikolova"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-01-06 17:05:08 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-01-06 17:05:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Dopamine agonists versus placebo or no intervention</NAME>
<DICH_OUTCOME CHI2="4.1755410624754505" CI_END="3.5400716343249163" CI_START="0.3487958346888398" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1111985603629284" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="28.153023641408915" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.549012050183206" LOG_CI_START="-0.45742871004237634" LOG_EFFECT_SIZE="0.04579167007041486" METHOD="MH" MODIFIED="2012-09-27 18:05:55 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24312225505616425" P_Q="1.0" P_Z="0.8584470694373814" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.43143468294005044" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="100.0" Z="0.17835133010677615">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Dopamine agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.90592065321976" CI_START="0.48101603562601103" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="1.671227664564453" LOG_CI_START="-0.3178404453147198" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2012-04-04 15:39:34 +0200" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-Koshy-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="19.453977020858034"/>
<DICH_DATA CI_END="3.629844786698178" CI_START="0.5813302298456056" EFFECT_SIZE="1.4526315789473685" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.5598880548648513" LOG_CI_START="-0.23557709264007373" LOG_EFFECT_SIZE="0.16215548111238876" MODIFIED="2012-04-04 15:39:34 +0200" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="0.4672601652603781" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.21833206203915587" WEIGHT="53.789085152896114"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 16:07:28 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.518350116546495" CI_START="0.007890655184634532" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-04 15:39:34 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="1.7817416127494958" STUDY_ID="STD-Uribe-1979" TOTAL_1="4" TOTAL_2="4" VAR="3.1746031746031744" WEIGHT="9.692177441259076"/>
<DICH_DATA CI_END="2.5179451589592223" CI_START="0.017237380100731836" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4010462669073642" LOG_CI_START="-1.7635287416585388" LOG_EFFECT_SIZE="-0.6812412373755872" MODIFIED="2012-04-04 15:39:34 +0200" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.27148207485071" STUDY_ID="STD-Vij-1979" TOTAL_1="9" TOTAL_2="7" VAR="1.6166666666666667" WEIGHT="17.064760384986776"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.17554106247545" CI_END="3.5400716343249155" CI_START="0.3487958346888399" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1111985603629284" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="28.1530236414089" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5490120501832059" LOG_CI_START="-0.4574287100423762" LOG_EFFECT_SIZE="0.04579167007041486" METHOD="MH" MODIFIED="2014-01-06 12:47:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.24312225505616436" P_Q="0.4017676174075262" P_Z="0.8584470694373812" Q="0.7030307863124623" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4314346829400501" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="100.0" Z="0.17835133010677626">
<NAME>Mortality stratified by type of hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Dopamine agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.343167478340138" CI_END="4.830291074722585" CI_START="0.3400960712531547" DF="2" EFFECT_SIZE="1.281703170598532" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" I2="40.17649391011103" ID="CMP-001.02.01" LOG_CI_END="0.683973302249845" LOG_CI_START="-0.46839838495328423" LOG_EFFECT_SIZE="0.1077874586482804" MODIFIED="2014-01-06 12:47:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1879493813230586" P_Z="0.7138788164410661" STUDIES="3" TAU2="0.5997806298193391" TOTAL_1="66" TOTAL_2="65" WEIGHT="90.30782255874092" Z="0.3666517310026398">
<NAME>Acute episode of hepatic encephalopathy</NAME>
<DICH_DATA CI_END="46.90592065321976" CI_START="0.48101603562601103" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="1.671227664564453" LOG_CI_START="-0.3178404453147198" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2012-04-08 16:36:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-Koshy-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="19.45397702085803"/>
<DICH_DATA CI_END="3.629844786698178" CI_START="0.5813302298456056" EFFECT_SIZE="1.4526315789473685" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.5598880548648513" LOG_CI_START="-0.23557709264007373" LOG_EFFECT_SIZE="0.16215548111238876" MODIFIED="2012-04-08 16:36:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="0.4672601652603781" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.21833206203915587" WEIGHT="53.78908515289612"/>
<DICH_DATA CI_END="2.5179451589592223" CI_START="0.017237380100731836" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4010462669073642" LOG_CI_START="-1.7635287416585388" LOG_EFFECT_SIZE="-0.6812412373755872" MODIFIED="2012-04-08 16:36:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.27148207485071" STUDY_ID="STD-Vij-1979" TOTAL_1="9" TOTAL_2="7" VAR="1.6166666666666667" WEIGHT="17.064760384986773"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.518350116546495" CI_START="0.007890655184634532" DF="0" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2014-01-06 12:47:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4486638441890194" STUDIES="2" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="9.692177441259075" Z="0.7576444908113672">
<NAME>Chronic hepatic encephalopathy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 17:11:54 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.518350116546495" CI_START="0.007890655184634532" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 17:11:51 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="1.7817416127494958" STUDY_ID="STD-Uribe-1979" TOTAL_1="4" TOTAL_2="4" VAR="3.1746031746031744" WEIGHT="9.692177441259075"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1755410624754505" CI_END="3.5400716343249163" CI_START="0.3487958346888398" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1111985603629282" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="28.153023641408915" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.549012050183206" LOG_CI_START="-0.45742871004237634" LOG_EFFECT_SIZE="0.04579167007041477" METHOD="MH" MODIFIED="2012-09-27 18:06:33 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24312225505616425" P_Q="0.8887997568437872" P_Z="0.8584470694373814" Q="0.01955050370351823" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.43143468294005044" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="100.0" Z="0.1783513301067761">
<NAME>Mortality stratified by liver disease</NAME>
<GROUP_LABEL_1>Dopamine agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2796573160704243" CI_END="22.16569899312543" CI_START="0.048383658606182316" DF="1" EFFECT_SIZE="1.0355952939497068" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="69.50900952059935" ID="CMP-001.03.01" LOG_CI_END="1.3456814312848324" LOG_CI_START="-1.3153012948744933" LOG_EFFECT_SIZE="0.015190068205169577" MODIFIED="2012-04-08 17:12:12 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07014363584479877" P_Z="0.9821474780813282" STUDIES="2" TAU2="3.398739092829996" TOTAL_1="29" TOTAL_2="27" WEIGHT="36.51873740584481" Z="0.022376685359254637">
<NAME>Fulminant liver failure</NAME>
<DICH_DATA CI_END="46.90592065321976" CI_START="0.48101603562601103" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="1.671227664564453" LOG_CI_START="-0.3178404453147198" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2012-04-08 16:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-Koshy-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="19.453977020858034"/>
<DICH_DATA CI_END="2.5179451589592223" CI_START="0.017237380100731836" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4010462669073642" LOG_CI_START="-1.7635287416585388" LOG_EFFECT_SIZE="-0.6812412373755872" MODIFIED="2012-04-08 16:36:42 +0200" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.27148207485071" STUDY_ID="STD-Vij-1979" TOTAL_1="9" TOTAL_2="7" VAR="1.6166666666666667" WEIGHT="17.064760384986776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8775240985223938" CI_END="3.1529585612948443" CI_START="0.536132772030595" DF="1" EFFECT_SIZE="1.3001555343744846" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.49871826293970656" LOG_CI_START="-0.27072764497197016" LOG_EFFECT_SIZE="0.11399530898386821" MODIFIED="2012-04-08 17:12:12 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34888080712155434" P_Z="0.5614109853213831" STUDIES="3" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="63.48126259415519" Z="0.580746996553119">
<NAME>Cirrhosis</NAME>
<DICH_DATA CI_END="3.629844786698178" CI_START="0.5813302298456056" EFFECT_SIZE="1.4526315789473685" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.5598880548648513" LOG_CI_START="-0.23557709264007373" LOG_EFFECT_SIZE="0.16215548111238876" MODIFIED="2012-04-08 17:12:12 +0200" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="0.4672601652603781" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.21833206203915587" WEIGHT="53.789085152896114"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 17:12:09 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.518350116546495" CI_START="0.007890655184634532" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 17:12:06 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="1.7817416127494958" STUDY_ID="STD-Uribe-1979" TOTAL_1="4" TOTAL_2="4" VAR="3.1746031746031744" WEIGHT="9.692177441259076"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1755410624754505" CI_END="3.5400716343249163" CI_START="0.3487958346888398" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1111985603629282" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="28.153023641408915" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.549012050183206" LOG_CI_START="-0.45742871004237634" LOG_EFFECT_SIZE="0.04579167007041477" METHOD="MH" MODIFIED="2014-01-06 17:04:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.24312225505616425" P_Q="0.4017676174075262" P_Z="0.8584470694373814" Q="0.7030307863124623" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.43143468294005044" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="100.0" Z="0.1783513301067761">
<NAME>Mortality stratified by intervention</NAME>
<GROUP_LABEL_1>Dopamine agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.343167478340138" CI_END="4.830291074722585" CI_START="0.3400960712531547" DF="2" EFFECT_SIZE="1.281703170598532" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" I2="40.17649391011103" ID="CMP-001.04.01" LOG_CI_END="0.683973302249845" LOG_CI_START="-0.46839838495328423" LOG_EFFECT_SIZE="0.1077874586482804" MODIFIED="2012-04-08 17:12:26 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1879493813230586" P_Z="0.7138788164410661" STUDIES="3" TAU2="0.5997806298193391" TOTAL_1="66" TOTAL_2="65" WEIGHT="90.30782255874092" Z="0.3666517310026398">
<NAME>Levodopa</NAME>
<DICH_DATA CI_END="46.90592065321976" CI_START="0.48101603562601103" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="1.671227664564453" LOG_CI_START="-0.3178404453147198" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2012-04-08 16:36:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-Koshy-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="19.453977020858034"/>
<DICH_DATA CI_END="3.629844786698178" CI_START="0.5813302298456056" EFFECT_SIZE="1.4526315789473685" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.5598880548648513" LOG_CI_START="-0.23557709264007373" LOG_EFFECT_SIZE="0.16215548111238876" MODIFIED="2012-04-08 16:36:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="0.4672601652603781" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.21833206203915587" WEIGHT="53.789085152896114"/>
<DICH_DATA CI_END="2.5179451589592223" CI_START="0.017237380100731836" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4010462669073642" LOG_CI_START="-1.7635287416585388" LOG_EFFECT_SIZE="-0.6812412373755872" MODIFIED="2012-04-08 16:36:43 +0200" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.27148207485071" STUDY_ID="STD-Vij-1979" TOTAL_1="9" TOTAL_2="7" VAR="1.6166666666666667" WEIGHT="17.064760384986776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.518350116546495" CI_START="0.007890655184634532" DF="0" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2014-01-06 17:04:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4486638441890194" STUDIES="2" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="9.692177441259076" Z="0.7576444908113672">
<NAME>Bromocriptine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 17:12:26 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.518350116546495" CI_START="0.007890655184634532" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 17:12:23 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="1.7817416127494958" STUDY_ID="STD-Uribe-1979" TOTAL_1="4" TOTAL_2="4" VAR="3.1746031746031744" WEIGHT="9.692177441259076"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.17554106247545" CI_END="2.590097397867397" CI_START="0.5940211762204097" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2403921568627454" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="28.1530236414089" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.4133160955720003" LOG_CI_START="-0.22619807260846467" LOG_EFFECT_SIZE="0.09355901148176778" METHOD="MH" MODIFIED="2012-09-27 18:06:54 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.24312225505616436" P_Q="0.36417195601740016" P_Z="0.5663239729193419" Q="0.8234551565633813" RANDOM="NO" SCALE="1000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="100.00000000000003" Z="0.5734737463445481">
<NAME>Mortality stratified by bias risk</NAME>
<GROUP_LABEL_1>Dopamine agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.518350116546502" CI_START="0.007890655184634532" DF="0" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.9303554862377668" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 17:13:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4486638441890195" STUDIES="2" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="10.58823529411765" Z="0.7576444908113671">
<NAME>Low bias risk</NAME>
<DICH_DATA CI_END="8.518350116546495" CI_START="0.007890655184634532" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 16:36:41 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="1.7817416127494958" STUDY_ID="STD-Uribe-1979" TOTAL_1="4" TOTAL_2="4" VAR="3.1746031746031744" WEIGHT="10.58823529411765"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 16:36:41 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.343167478340138" CI_END="2.9070803910568412" CI_START="0.6330428446714499" DF="2" EFFECT_SIZE="1.3565789473684213" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" I2="40.17649391011103" ID="CMP-001.05.02" LOG_CI_END="0.4634570417152632" LOG_CI_START="-0.19856689570981273" LOG_EFFECT_SIZE="0.1324450730027253" MODIFIED="2012-04-08 17:13:14 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1879493813230586" P_Z="0.4329086158234797" STUDIES="3" TAU2="0.0" TOTAL_1="66" TOTAL_2="65" WEIGHT="89.41176470588238" Z="0.7842241294922916">
<NAME>Unclear bias risk</NAME>
<DICH_DATA CI_END="46.90592065321976" CI_START="0.48101603562601103" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="1.671227664564453" LOG_CI_START="-0.3178404453147198" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2012-04-08 17:13:14 +0200" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-Koshy-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="6.27450980392157"/>
<DICH_DATA CI_END="2.5179451589592223" CI_START="0.017237380100731836" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4010462669073642" LOG_CI_START="-1.7635287416585388" LOG_EFFECT_SIZE="-0.6812412373755872" MODIFIED="2012-04-08 17:13:09 +0200" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.27148207485071" STUDY_ID="STD-Vij-1979" TOTAL_1="9" TOTAL_2="7" VAR="1.6166666666666667" WEIGHT="23.529411764705888"/>
<DICH_DATA CI_END="3.629844786698178" CI_START="0.5813302298456056" EFFECT_SIZE="1.4526315789473685" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.5598880548648513" LOG_CI_START="-0.23557709264007373" LOG_EFFECT_SIZE="0.16215548111238876" MODIFIED="2012-04-08 17:13:12 +0200" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="0.4672601652603781" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.21833206203915587" WEIGHT="59.60784313725491"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1755410624754505" CI_END="3.5400716343249163" CI_START="0.3487958346888398" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1111985603629282" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="38" I2="28.153023641408915" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.549012050183206" LOG_CI_START="-0.45742871004237634" LOG_EFFECT_SIZE="0.04579167007041477" METHOD="MH" MODIFIED="2014-01-06 17:05:08 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.24312225505616425" P_Q="0.4017676174075262" P_Z="0.8584470694373814" Q="0.7030307863124623" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.43143468294005044" TOTALS="YES" TOTAL_1="73" TOTAL_2="71" WEIGHT="100.0" Z="0.1783513301067761">
<NAME>Mortality stratified by trial design</NAME>
<GROUP_LABEL_1>Dopamine agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.343167478340138" CI_END="4.830291074722585" CI_START="0.3400960712531547" DF="2" EFFECT_SIZE="1.281703170598532" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="37" I2="40.17649391011103" ID="CMP-001.06.01" LOG_CI_END="0.683973302249845" LOG_CI_START="-0.46839838495328423" LOG_EFFECT_SIZE="0.1077874586482804" MODIFIED="2014-01-06 17:05:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1879493813230586" P_Z="0.7138788164410661" STUDIES="3" TAU2="0.5997806298193391" TOTAL_1="66" TOTAL_2="65" WEIGHT="90.30782255874092" Z="0.3666517310026398">
<NAME>Parallel group</NAME>
<DICH_DATA CI_END="46.90592065321976" CI_START="0.48101603562601103" EFFECT_SIZE="4.75" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="1.671227664564453" LOG_CI_START="-0.3178404453147198" LOG_EFFECT_SIZE="0.6766936096248666" MODIFIED="2012-04-08 16:59:22 +0200" MODIFIED_BY="[Empty name]" ORDER="2332" O_E="0.0" SE="1.168388453788965" STUDY_ID="STD-Koshy-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.3651315789473684" WEIGHT="19.453977020858034"/>
<DICH_DATA CI_END="3.629844786698178" CI_START="0.5813302298456056" EFFECT_SIZE="1.4526315789473685" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.5598880548648513" LOG_CI_START="-0.23557709264007373" LOG_EFFECT_SIZE="0.16215548111238876" MODIFIED="2012-04-08 16:59:22 +0200" MODIFIED_BY="[Empty name]" ORDER="2330" O_E="0.0" SE="0.4672601652603781" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.21833206203915587" WEIGHT="53.789085152896114"/>
<DICH_DATA CI_END="2.5179451589592223" CI_START="0.017237380100731836" EFFECT_SIZE="0.20833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4010462669073642" LOG_CI_START="-1.7635287416585388" LOG_EFFECT_SIZE="-0.6812412373755872" MODIFIED="2012-04-08 16:59:22 +0200" MODIFIED_BY="[Empty name]" ORDER="2333" O_E="0.0" SE="1.27148207485071" STUDY_ID="STD-Vij-1979" TOTAL_1="9" TOTAL_2="7" VAR="1.6166666666666667" WEIGHT="17.064760384986776"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.518350116546495" CI_START="0.007890655184634532" DF="0" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 17:13:30 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4486638441890194" STUDIES="2" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="9.692177441259076" Z="0.7576444908113672">
<NAME>Cross-over</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 17:13:30 +0200" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.0" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.518350116546495" CI_START="0.007890655184634532" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9303554862377664" LOG_CI_START="-2.1028869345272274" LOG_EFFECT_SIZE="-0.5862657241447305" MODIFIED="2012-04-08 17:13:27 +0200" MODIFIED_BY="[Empty name]" ORDER="2331" O_E="0.0" SE="1.7817416127494958" STUDY_ID="STD-Uribe-1979" TOTAL_1="4" TOTAL_2="4" VAR="3.1746031746031744" WEIGHT="9.692177441259076"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8967679701141567" CI_END="100.5543502591826" CI_START="0.08886777523007855" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.9893212268405724" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="65.47876770535433" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="2.002400864119128" LOG_CI_START="-1.0512556920877736" LOG_EFFECT_SIZE="0.47557258601567715" METHOD="MH" MODIFIED="2014-01-06 17:01:28 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.08875748983001741" P_Q="1.0" P_Z="0.5415408494169432" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="4.668081457877369" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.610484593449578">
<NAME>Hepatic encephalopathy</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2435.692067476113" CI_START="0.5029371390404684" EFFECT_SIZE="35.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="3.3866223817238947" LOG_CI_START="-0.2984862930233436" LOG_EFFECT_SIZE="1.5440680443502757" MODIFIED="2012-04-08 15:44:04 +0200" MODIFIED_BY="[Empty name]" ORDER="2326" O_E="0.0" SE="2.164651077128664" STUDY_ID="STD-Morgan-1980" TOTAL_1="3" TOTAL_2="2" VAR="4.685714285714286" WEIGHT="34.397565232669564"/>
<DICH_DATA CI_END="2.1340864638572503" CI_START="0.3172757472662136" EFFECT_SIZE="0.8228571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.32921201115938875" LOG_CI_START="-0.49856312434147826" LOG_EFFECT_SIZE="-0.0846755565910448" MODIFIED="2012-04-08 15:44:04 +0200" MODIFIED_BY="[Empty name]" ORDER="2325" O_E="0.0" SE="0.4862392121462145" STUDY_ID="STD-Michel-1980" TOTAL_1="37" TOTAL_2="38" VAR="0.2364285714285714" WEIGHT="65.60243476733044"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="3.3315356149308926" CI_END="2.674112653621475" CI_START="0.17099268216133406" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.6762053645485951" ESTIMABLE="YES" I2="39.967623607665175" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.427179699042502" LOG_CI_START="-0.7670224753678249" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.16992138816266145" MODIFIED="2014-01-06 17:01:54 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.18904565804028528" P_Q="1.0" P_Z="0.5770074837641289" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.6957788089185905" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="100.0" Z="0.5577611699900238">
<NAME>Hepatic encephalopathy paired data</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.4884836764882698" CI_START="0.7692356380699823" EFFECT_SIZE="1.0700442470478533" ESTIMABLE="YES" ESTIMATE="0.0677" LOG_CI_END="0.1727440763022319" LOG_CI_START="-0.11394060345253162" LOG_EFFECT_SIZE="0.02940173642485013" MODIFIED="2012-04-04 15:34:31 +0200" MODIFIED_BY="[Empty name]" ORDER="2327" SE="0.1684" STUDY_ID="STD-Michel-1980" TOTAL_1="1" TOTAL_2="1" WEIGHT="67.9532072806477"/>
<IV_DATA CI_END="2.1122677510481824" CI_START="3.23349414475967E-5" EFFECT_SIZE="0.008264384674722595" ESTIMABLE="YES" ESTIMATE="-4.7958" LOG_CI_END="0.3247489685172833" LOG_CI_START="-4.490327921140513" LOG_EFFECT_SIZE="-2.082789476311615" MODIFIED="2012-04-04 15:34:31 +0200" MODIFIED_BY="[Empty name]" ORDER="2328" SE="2.8284" STUDY_ID="STD-Morgan-1980" TOTAL_1="1" TOTAL_2="1" WEIGHT="5.658874967828496"/>
<IV_DATA CI_END="4.439372599696152" CI_START="0.06407422768607997" EFFECT_SIZE="0.5333379517119291" ESTIMABLE="YES" ESTIMATE="-0.6286" LOG_CI_END="0.6473215971995181" LOG_CI_START="-1.1933166198482863" LOG_EFFECT_SIZE="-0.2729975113243841" MODIFIED="2012-04-04 15:34:31 +0200" MODIFIED_BY="[Empty name]" ORDER="2329" SE="1.0812" STUDY_ID="STD-Uribe-1979" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.3879177515238"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.2170719471251124" CI_END="5.2350815555996455" CI_START="-0.9948223817135022" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="2.120129586943072" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.7189234517972873" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.32636240676569644" MODIFIED="2012-04-08 17:28:31 +0200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.6412800776960215" P_Q="1.0" P_Z="0.18220052064361328" Q="0.0" RANDOM="YES" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="1.33401017889799">
<NAME>Adverse events paired data</NAME>
<GROUP_LABEL_1>Dopamine agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours dopamine agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>OR</EFFECT_MEASURE>
<IV_DATA CI_END="5.949706546118186" CI_START="-3.351106546118187" EFFECT_SIZE="1.2993" ESTIMABLE="YES" ESTIMATE="1.2993" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 17:28:30 +0200" MODIFIED_BY="[Empty name]" ORDER="2334" SE="2.3727" STUDY_ID="STD-Morgan-1980" TOTAL_1="1" TOTAL_2="1" WEIGHT="44.86636304788608"/>
<IV_DATA CI_END="6.983206912509532" CI_START="-1.407006912509532" EFFECT_SIZE="2.7881" ESTIMABLE="YES" ESTIMATE="2.7881" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-08 17:28:30 +0200" MODIFIED_BY="[Empty name]" ORDER="2335" SE="2.1404" STUDY_ID="STD-Uribe-1979" TOTAL_1="1" TOTAL_2="1" WEIGHT="55.13363695211391"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-02-05 19:20:32 +0100" MODIFIED_BY="dimitrinka nikolova">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-01-13 17:31:15 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAMYCAYAAADhNmFtAABOCklEQVR42u2dD4RVW///H5IkyZBc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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-01-10 12:02:36 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. Risk of bias graph: review authors' judgements about all risk of bias items presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Mortality 20% RRR.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2014-02-05 19:20:32 +0100" MODIFIED_BY="Christian Gluud" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Trial sequential analysis of dopamine agents versus placebo or no intervention in participants with hepatic encephalopathy. </B>
<BR/>
<BR/>The outcome measure is mortality. The analysis was performed with an event rate of 54% (Pc) in the control group, a risk ratio (RR) reduction of 20%, alpha 5%, beta 20%, and diversity 0%. The cumulative Z-curve does not cross the naive 5% statistical boundaries (dotted horizontal lines) or the trial sequential boundaries for benefits or harms (inward sloping etched lines). The results show that the diversity-adjusted required information size was 673 participants, corresponding to 21% of the total sample size in the included trials. The programme did not even draw futility boundaries. Accordingly, the meta-analysis does not recommend or refute an intervention effect; data are simply too few.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-01-13 17:20:44 +0100" MODIFIED_BY="dimitrinka nikolova">
<APPENDIX ID="APP-01" MODIFIED="2014-01-13 17:20:44 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<TITLE MODIFIED="2013-05-23 13:20:20 +0200" MODIFIED_BY="dimitrinka nikolova">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-01-13 17:20:44 +0100" MODIFIED_BY="dimitrinka nikolova">
<TABLE COLS="3" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>January 2014.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(dopa* OR 'dopa decarboxylase' OR levodopa OR bromocriptine) AND ('liver cirrhosis' OR 'hepatic encephalopathy')</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 12 of 12, 2013.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Dopamine Agents] explode all trees</P>
<P>#2 MeSH descriptor: [Dopa Decarboxylase] explode all trees</P>
<P>#3 MeSH descriptor: [Levodopa] explode all trees</P>
<P>#4 MeSH descriptor: [Bromocriptine] explode all trees</P>
<P>#5 dopa* or dopa decarboxylase or levodopa or bromocriptine</P>
<P>#6  #1 or #2 or #3 or #4 or #5</P>
<P>#7 MeSH descriptor: [Liver Cirrhosis] explode all trees</P>
<P>#8 MeSH descriptor: [Hepatic Encephalopathy] explode all trees</P>
<P>#9 (liver cirrhosis or hepatic encephalopathy)</P>
<P>#10 #7 or #8 or #9</P>
<P>#11 #6 and #10</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to January 2014.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Dopamine Agents/</P>
<P>2. exp Dopa Decarboxylase/</P>
<P>3. exp Levodopa/</P>
<P>4. exp Bromocriptine/</P>
<P>5. (dopa* or dopa decarboxylase or levodopa or bromocriptine).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>6. 1 or 2 or 3 or 4 or 5</P>
<P>7. exp Liver Cirrhosis/</P>
<P>8. exp Hepatic Encephalopathy/</P>
<P>9. (liver cirrhosis or hepatic encephalopathy).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>10. 7 or 8 or 9</P>
<P>11. 6 and 10</P>
<P>12. (random* or blind* or placebo* or meta-analysis).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>13. 11 and 12</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to January 2014.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp dopamine receptor stimulating agent/</P>
<P>2. exp dopamine receptor blocking agent/</P>
<P>3. exp aromatic levo amino acid decarboxylase/</P>
<P>4. exp LEVODOPA/</P>
<P>5. exp BROMOCRIPTINE/</P>
<P>6. (dopa* or dopa decarboxylase or levodopa or bromocriptine).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer]</P>
<P>7. 1 or 2 or 3 or 4 or 5 or 6</P>
<P>8. exp liver cirrhosis/</P>
<P>9. exp hepatic encephalopathy/</P>
<P>10. (liver cirrhosis or hepatic encephalopathy).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer]</P>
<P>11. 8 or 9 or 10</P>
<P>12. 7 and 11</P>
<P>13. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer]</P>
<P>14. 12 and 13</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index-Expanded (<A HREF="http://apps.webofknowledge.com">http://apps.webofknowledge.com</A>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to January 2014.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#5 20 #4 AND #3</P>
<P>#4 1,186,796 TS=(random* or blind* or placebo* or meta-analysis)</P>
<P>#3 205 #2 AND #1</P>
<P>#2 54,464 TS=(liver cirrhosis or hepatic encephalopathy)</P>
<P>#1 198,470 TS=(dopa* or dopa decarboxylase or levodopa or bromocriptine)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Five randomised controlled trials included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Five randomised controlled trials (eight references) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 references assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;298 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;294 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;Four additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;281 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Nine records referring to six observational studies and two cross-over trials comparing dopamine agents versus active interventions were excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>